AzTrials
AzTrials

Ischemic Mitral RegurgitationSURVIVENCT04023058

Stress Echo for Ischemic Mitral Valve Surgery

A study testing Mitral surgery in people with Ischemic Mitral Regurgitation, run by Saint Petersburg State University, Russia at 1 site in Russia.

Suspended

Paused. Enrolment is on hold for now and may resume.

Official record
Search all trials

Trial summary

Comparison patients with CABG alone vs. CABG+mitral surgery with non-massive ischaemic mitral regurgitation (IMR) depending on stress echo data. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ischemic Mitral Regurgitation
What is being tested?
Mitral surgery
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteRussia
Study dates
1 Jan 2020to 31 Dec 2027
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Ischemic MR, ERO≥0.2 cm2 and RV≥30 ml.
  • Indication for CABG

Who cannot join

  • Unwillingness to give informed consent and to enter a regular follow-up program.
  • Contraindications for SE.

Trial locations and contacts

1 site in 1 country.

Russia1 site
  • St. Petersburg State University

    Saint Petersburg

Other trials in Russia

About this study

Comparison patients with CABG alone vs. CABG+mitral surgery with non-massive ischaemic mitral regurgitation (IMR) depending on stress echo data.

Read the detailed description

Chronic ischaemic mitral regurgitation (IMR) is a frequent complication of coronary artery disease (CAD), and is associated with a poor prognosis and outcome. The role of concomitant mitral valve surgery for IMR in patients undergoing coronary artery bypass grafting (CABG) remains controversial. After myocardial infarction IMR is associated with poor outcome and prognosis with double mortality rates, it reduces survival following surgical or percutaneous revascularization. However, there is no consensus on the cut-off value of IMR. The thresholds to define severe secondary mitral regurgitation are need to be evaluated with regards to their impact on prognosis after mitral valve intervention. The European guidelines is defined effective regurgitant orifice (ERO)-0.2 cm2 and regurgitant volume (RV)-30ml, as the threshold for severe IMR, because of severe prognosis of this group. Whereas American guidelines are defined it as ERO-0.4 cm2 and RV-60ml, as it was no evidence to impact intervention on the IMR with ERO-0.2 cm2 and RV-30ml. Partly it's explained by the dynamic nature of the secondary MR. About 30% of patients from the group with non-massive regurgitation at rest, have dramatically increasing it during exercise. However, some patient have not changes or decreasing IMR during exercise and, probably, they have not such a negative impact on the hemodynamic by IMR. The pervious comparative studies, that were the base for recommendations did not differ the patients with and without changes IMR during exercise. The current guidelines doesn't support the stress echo (SE) exams before operation for assessing necessity in mitral valve operation. It's due to lack of information that prove of influence for survival after surgery depending on IMR dynamic parameters.

IMR study hypothesis: Stress echocardiography data, including ERO, RV, pulmonary pressure (PA) pressure, beta-lines - B-lines, contractile reserve, could be indications for mitral valve intervention in patient with CAD and chronic secondary mitral regurgitation, undergoing CABG. The patients of the group with non-massive (ERO-0.2 cm2 and RV-30ml) IMR have positive effect by mitral surgery if they have increasing IMR during exercise test. The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with non-massive non-operated subgroup.

Aim: To assess the value of stress echo testing for ischemic mitral surgery indication in patients undergoing CABG.

Inclusion criteria for all projects are:

  1. Age > 18 years
  2. IMR, ERO≥0.2 cm2 and RV≥30 ml.
  3. Indication for CABG

Exclusion criteria for all projects are:

  1. Unwillingness to give informed consent and to enter a regular follow-up program.
  2. Contraindications for stress echo.

Methods and design:

  1. In a prospective multicenter international randomized study, we will recruit patients whom CABG is planned.
  2. Conventional transthoracic echo. Patients will include into two groups: Group 1 - "Non-massive IMR" - ERO-0.2-0.39 cm2, and RV-30-59ml. Group 2 - "Massive IMR" - ERO≥0.4 cm2 and RV≥60 ml.
  3. Randomization of Group 1 (surgery/non-surgery).
  4. Exercise stress echocardiography of all the patients (Group 1 and Group 2). regional wall motion abnormality (RWMA), ejection fraction (EF), end diastolic volume (EDV), end systolic volume (ESV), contractile reserve, B-lines, ERO, RV, PA pressure at rest and during stress.
  5. 1-year clinical outcomes
  6. 1-year transthoracic echo data.
  7. 1-year stress echocardiography data.
  8. 3-year clinical outcomes
  9. 3-year transthoracic echo data.
  10. 3-year stress echocardiography data. Primary end-points: death, myocardial infarction, new hospital readmission, heart transplant, ventricular assist device implantation, aborted sudden death, pulmonary oedema (MACE).

Secondary end-points: physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data.

Expected results. Group 1, CABG - subgroup, CABG+mitral surgery subgroup. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echocardiography), EDV, left atrium volume, EF at rest and during SE, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with pre-operative data in CABG+mitral surgery subgroup already in 1-year follow-up. It's expected the improvement of physical capacity (changes in Watts, minutes of stress echo), EDV, left atrium volume, EF at rest and during stress echo, ERO, RV, PA pressure, B-lines, contractile reserve at rest and during exercise in comparison with CABG-subgroup already in 1-year follow-up. It's expected that more pronounce changes will be in CABG+mitral surgery subgroup with previously increasing IMR. The worst results are expected in CABG-subgroup with previously increasing IMR during exercise. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc). We expected reduced MACE till 3 year in CABG+mitral surgery subgroup with increasing IMR in comparison with CABG-subgroup with increasing IMR.

Group 2, The group with massive IMR (ERO≥0.4 cm2 and RV≥60 ml) will be better according clinic, echo, stress echo results in comparison with CABG-subgroup with increasing IMR from group 1. There will be clarified which parameters would be more correlate with the clinic improvement (contractile reserve, B-lines, ERO etc).

Being tested
Mitral surgery
Keywords
ischemic mitral regurgitation, mitral surgery, stress echo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mitral surgeryProcedure or surgery

    Guidelines approved mitral surgery

Study groups in NCT04023058
Study groupRoleWhat they receive
CABG/increasing MRNo interventionnon-massive IMR with increasing IMR during exercise - CABG only
CABG+mitral surgery (MS)/increasing MRExperimentalnon-massive IMR with increasing IMR during exercise - CABG+ mitral surgery
Receives: Procedure: Mitral surgery
CABG/non-increasing MRNo interventionnon-massive IMR non-increasing IMR during exercise - CABG only
CABG+MS/non-increasing MRExperimentalnon-massive IMR non-increasing IMR - CABG+ mitral surgery
Receives: Procedure: Mitral surgery
Control 1Othermassive IMR at rest without increasing during exercise - CABG+ mitral surgery
Receives: Procedure: Mitral surgery
Control 2Othermassive IMR at rest with increasing during exercise - CABG+ mitral surgery
Receives: Procedure: Mitral surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. myocardial infarction

    myocardial infarction

    Measured: during 3 year

  2. all-cause death

    all-cause death

    Measured: during 3 year

  3. new hospital readmission

    new hospitalization

    Measured: during 3 year from including

  4. re-operation

    percutaneous coronary intervention, coronary bypass surgery, heart transplant

    Measured: during 3 year

  5. cardiac death

    cardiac death

    Measured: during 3 year

Secondary outcomes (9)
  1. physical capacity

    Change in Watts during stress test

    Measured: Change from Baseline of physical capacity in Watts at 12 months, at 3 years

  2. end diastolic volume of left ventricle

    Change in milliliters by echocardiography

    Measured: Change from Baseline of end diastolic volume of left ventricle at 12 months, at 3 years

  3. left atrium volume

    Change in milliliters by echocardiography

    Measured: Change from Baseline of left atrium volume at 12 months, at 3 years

  4. ejection fraction at rest and during stress echo

    Change in percent by echocardiography at rest and at the peak of exercise during stress test

    Measured: Change from Baseline of ejection fraction at 12 months, at 3 years

  5. effective regurgitant orifice

    Change in centimeter square of mitral effective regurgitant orifice by echocardiography

    Measured: Change from Baseline at 12 months, at 3 years

  6. right ventricle size

    Change in centimeter of right ventricle by echocardiography

    Measured: Change from Baseline at 12 months, at 3 years

  7. pulmonary artery pressure pressure

    Change in mm Hg of pulmonary pressure by echocardiography

    Measured: Change from Baseline at 12 months, at 3 years

  8. B-lines

    counts of B-lines during by stress echocardiography

    Measured: Change from Baseline at 12 months, at 3 years

  9. Contractile reserve

    Change in contractile reserve by stress echocardiography

    Measured: Change from Baseline at 12 months, at 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2019
  2. Study start1 Jan 2020
  3. Primary completion31 Dec 2024 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Why it stopped: Slow recruitment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04023058
Sponsor's protocol ID
2/2019
Acronym
SURVIVE
Status last verified
Oct 2022
First submitted
30 Jun 2019
Last updated
20 Oct 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Study Protocol, Clinical study report

Questions about this trial

What is this clinical trial studying?

A study testing Mitral surgery in people with Ischemic Mitral Regurgitation, run by Saint Petersburg State University, Russia at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: paused, as of the sponsor's last update on 20 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

myocardial infarction (time frame: during 3 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in